Esperion Therapeutics, Inc. (ESPR)

$1.15

-0.09

(-7.26%)▲

Market is closed - opens 7 PM, 21 Sep 2023

Insights on Esperion Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 18.81M → 25.78M (in $), with an average increase of 14.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -61.71M → -49.93M (in $), with an average increase of 23.6% per quarter

  • Vs HLN

    In the last 1 year, Haleon Plc Spon Ads has given 38.0% return, outperforming this stock by 120.6%

Performance

  • $1.15
    $1.37
    $1.15
    downward going graph

    0.0%

    Downside

    Day's Volatility :16.06%

    Upside

    16.06%

    downward going graph
  • $1.12
    $8.87
    $1.15
    downward going graph

    2.61%

    Downside

    52 Weeks Volatility :87.37%

    Upside

    87.03%

    downward going graph

Returns

PeriodEsperion Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-12.37%
0.0%
0.0%
6 Months
-18.42%
3.0%
-0.5%
1 Year
-82.56%
7.2%
0.4%
3 Years
-96.68%
27.5%
19.1%

Highlights

Market Capitalization
132.7M
Book Value
- $3.69
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.48
PEG Ratio
-4.78
Wall Street Target Price
11.13
Profit Margin
-252.82%
Operating Margin TTM
-193.14%
Return On Assets TTM
-39.41%
Return On Equity TTM
-260.79%
Revenue TTM
87.9M
Revenue Per Share TTM
1.07
Quarterly Revenue Growth YOY
36.9%
Gross Profit TTM
-70.4M
EBITDA
-169.5M
Diluted Eps TTM
-2.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.04
EPS Estimate Next Year
0.07
EPS Estimate Current Quarter
-0.61
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    80%Buy
    13%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Esperion Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
11
11
Hold
2
3
4
Sell
1
2
2

Analyst Forecast

What analysts predicted

Upside of 867.83%

Current $1.15
Target $11.13

Technicals Summary

Sell

Neutral

Buy

Esperion Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
-16.22%
-18.42%
-82.56%
-96.68%
-97.13%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.98%
19.04%
8.68%
15.61%
-4.03%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-1.57%
1.59%
37.97%
9.85%
9.85%
Zoetis Inc.
Zoetis Inc.
0.65%
9.47%
20.33%
13.05%
102.58%
Viatris Inc.
Viatris Inc.
-12.18%
2.38%
9.4%
-39.47%
-39.47%
Catalent, Inc.
Catalent, Inc.
4.67%
-28.84%
-42.85%
-44.45%
11.42%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
NA
NA
-4.78
-2.04
-2.61
-0.39
0.0
-3.69
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
63.98
63.98
1.87
2.35
0.11
0.08
0.0
18.99
Haleon Plc Spon Ads
Haleon Plc Spon Ads
23.82
23.82
NA
0.0
0.06
0.04
0.01
3.56
Zoetis Inc.
Zoetis Inc.
38.47
38.47
3.53
5.44
0.48
0.14
0.01
10.04
Viatris Inc.
Viatris Inc.
7.07
7.07
NA
2.97
0.09
0.03
0.04
17.38
Catalent, Inc.
Catalent, Inc.
211.02
NA
1.18
1.01
-0.05
0.0
0.0
25.61
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
Buy
$132.7M
-97.13%
NA
-252.82%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$10.9B
-4.03%
63.98
10.54%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.9B
9.85%
23.82
10.78%
Zoetis Inc.
Zoetis Inc.
Buy
$84.1B
102.58%
38.47
26.92%
Viatris Inc.
Viatris Inc.
Hold
$13.0B
-39.47%
7.07
11.88%
Catalent, Inc.
Catalent, Inc.
Buy
$8.5B
11.42%
211.02
-5.43%

Institutional Holdings

  • Wasatch Advisors Inc.

    12.28%

  • Armistice Capital, LLC

    8.59%

  • Point72 Asset Management, L.P.

    4.65%

  • Meditor Group Ltd

    4.12%

  • Vanguard Group Inc

    3.98%

  • Bellevue Group AG

    3.93%

Corporate Announcements

  • Esperion Therapeutics, Inc. Earnings

    Esperion Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.

Organization
Esperion Therapeutics, Inc.
Employees
199
CEO
Mr. Sheldon L. Koenig
Industry
Health Technology

Discover More

FAQs